copiktra: Pharmaceutical manufacturers, suppliers, and packagers

Subscribe to access the full database, or Get Started Free
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Secura	COPIKTRA	duvelisib	CAPSULE;ORAL	211155	NDA	Secura Bio, Inc	73116-215-28	28 CAPSULE in 1 PACKAGE (73116-215-28)	2018-09-25
Secura	COPIKTRA	duvelisib	CAPSULE;ORAL	211155	NDA	Secura Bio, Inc	73116-215-56	56 CAPSULE in 1 PACKAGE (73116-215-56)	2018-09-25
Secura	COPIKTRA	duvelisib	CAPSULE;ORAL	211155	NDA	Secura Bio, Inc	73116-225-28	28 CAPSULE in 1 PACKAGE (73116-225-28)	2018-09-25
Secura	COPIKTRA	duvelisib	CAPSULE;ORAL	211155	NDA	Secura Bio, Inc	73116-225-56	56 CAPSULE in 1 PACKAGE (73116-225-56)	2018-09-25
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: July 29, 2025

Introduction

COPIKTRA (idelalisib) is an oral targeted therapy developed by Gilead Sciences, Inc., primarily used for treating certain hematologic malignancies, including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and follicular lymphoma (FL). Since its regulatory approval, the supply chain dynamics for COPIKTRA have become increasingly crucial as Gilead seeks to ensure reliable access to this specialized medicine amidst evolving market demands and manufacturing challenges. This article provides an in-depth analysis of the key suppliers involved in the manufacturing and distribution of COPIKTRA, examining their roles, quality standards, and the strategic landscape shaping the drug’s supply chain.

Manufacturing Bases and Primary Suppliers

1. Active Pharmaceutical Ingredient (API) Suppliers

The core of any pharmaceutical production entails sourcing high-quality APIs. For COPIKTRA, the API—idelalisib—is synthesized through complex chemical processes, necessitating suppliers with stringent quality controls and advanced chemical manufacturing capabilities.

Gilead Sciences' In-house Production: Initially, Gilead maintained internal API manufacturing facilities to ensure quality control, especially for high-value targeted therapies like idelalisib. Internal manufacturing reduces supply chain vulnerabilities and is characteristic of firms with significant R&D and manufacturing investments (see [1]).
External API Suppliers: Despite internal production, Gilead may source APIs from specialized chemical manufacturers globally, including regions known for fine chemical synthesis such as India and China. These countries are pivotal in the API supply chain, providing cost-effective, high-volume chemical synthesis services aligned with Good Manufacturing Practices (GMP).

2. Finished Dosage Form (FDF) Manufacturing

The final formulation of COPIKTRA involves blending, encapsulation, and packaging processes carried out by licensed pharmaceutical contract manufacturing organizations (CMOs).

Gilead’s Contract Manufacturers: Gilead collaborates with multiple CMOs across North America and Europe, leveraging their capacity to meet production standards and regulatory compliance. These include companies like Fresenius Kabi, CordenPharma, and Patheon (a Thermo Fisher Scientific company). They are integral in ensuring scale-up and timely delivery of finished capsules.
Global Supply Chain Risks: Dependence on international CMOs exposes supply chains to geopolitical, logistical, and regulatory risks. Recent disruptions, especially during the COVID-19 pandemic, underscore the importance of diversified CMO networks.

Distribution and Logistics

3. Distribution Partners and Wholesale Suppliers

Gilead’s Distribution Strategy: Gilead distributes COPIKTRA primarily through authorized distributors, wholesalers, and specialty pharmacies. Major US logistics partners include AmerisourceBergen, McKesson, and Cardinal Health—all of which have extensive networks for specialty drugs.
Global Markets: In Europe and Asia, Gilead partners with regional distributors licensed for oncology medications, ensuring compliance with local regulatory frameworks.

4. Regulatory and Quality Assurance

Ensuring consistent supply hinges on adherence to Good Distribution Practices (GDP) and Good Manufacturing Practices (GMP). Suppliers must attain accreditation from regulatory agencies such as the FDA, EMA, and PMDA to operate effectively.

Key Suppliers and Supply Chain Dynamics

5. Raw Material Suppliers

The synthesis of idelalisib requires multiple raw materials, including key intermediates and specialized chemicals.

Chemical Suppliers: Suppliers like BASF, Sigma-Aldrich (a part of Merck KGaA), and Thermo Fisher Scientific supply reagents and raw chemicals used in API synthesis and formulation.
Biopharmaceutical Raw Materials: Not applicable for COPIKTRA as it is a small-molecule drug; however, ensuring raw material purity is critical.

6. Contract Research and Development (R&D) Partners

Although not traditional suppliers, external R&D organizations and CMO partners facilitate ongoing formulation optimization, stability testing, and process validation.

Supply Chain Challenges and Strategic Implications

A. Supply Chain Vulnerabilities

The global COVID-19 pandemic accentuated vulnerabilities in pharma supply chains, especially in API sourcing from China and India. Gilead responded by increasing buffers and diversifying supplier bases [[2]]. Continuous monitoring and strategic stockpiling are vital to mitigate shortages.

B. Regulatory Scrutiny and Quality Standards

Suppliers must comply with GMP to ensure product safety and efficacy. Non-compliance risks recalls, regulatory actions, or disruptions in supply.

C. Market Demand and Production Scalability

As indications for COPIKTRA expand, reliable scaling from API and formulation suppliers will underpin Gilead’s ability to meet increasing demand without compromising quality or timelines.

Future Outlook and Strategic Considerations

Vertical Integration vs. Outsourcing: Gilead’s strategy appears to favor a hybrid model, balancing in-house manufacturing with a network of trusted CMOs to optimize capacity and reduce reliance on single sources.
Supply Chain Transparency: Increasing regulatory and public scrutiny demand transparent supply chains. Gilead’s ongoing efforts include supplier audits and compliance programs, aiming to uphold high standards globally.
Emerging Technologies: Adoption of digital supply chain management tools, including blockchain and real-time tracking, could further enhance resilience and traceability.

Key Takeaways

Gilead’s supply chain for COPIKTRA involves internally produced APIs complemented by external chemical suppliers, primarily in Asia.
Finished dosage manufacturing is decentralized, involving multiple CMOs across North America and Europe, reducing logistics risks.
Distribution relies on established wholesalers and specialty pharmacies, emphasizing the importance of rigorous quality assurance.
Supply chain vulnerabilities, particularly raw material sourcing and manufacturing disruptions, necessitate proactive diversification strategies.
Continuous regulatory compliance and technological upgrades are vital for maintaining supply reliability amid expanding market needs.

FAQs

1. Who are the main API suppliers for COPIKTRA?
While Gilead Sciences primarily relies on its internal manufacturing, key chemical intermediates are sourced from reputable suppliers in regions like India and China, including companies such as BASF and Sigma-Aldrich.

2. What role do contract manufacturing organizations play in COPIKTRA’s supply chain?
CMOs handle the formulation, encapsulation, and packaging of COPIKTRA, ensuring scalability, compliance with GMP, and timely distribution across global markets.

3. How does Gilead ensure the quality of its COPIKTRA supply chain?
Gilead enforces strict supplier qualification, audits, and compliance with regulatory standards such as GMP and GDP, to ensure product safety and efficacy.

4. What are the main logistical challenges facing COPIKTRA’s supply chain?
Global disruptions, raw material shortages, geopolitical tensions, and regulatory hurdles threaten supply continuity. Diversifying supplier bases and maintaining strategic stocks mitigate these risks.

5. How might future market expansion impact COPIKTRA’s supply chain?
Increased demand due to broader indications may necessitate scaling manufacturing and sourcing capacities, emphasizing the importance of flexible, diversified supply chain strategies.

References

[1] Gilead Sciences Annual Reports, 2022.
[2] FDA Supply Chain Initiative, 2021.

Suppliers and packagers for copiktra

copiktra

Suppliers for the Pharmaceutical Drug: COPIKTRA (Table of Accessories)